US 12,441,815 B2
Compositions and methods for diagnosis of cardiovascular disease
Yury Miller, San Diego, CA (US); Ayelet Gonen, La Jolla, CA (US); Sotirios Tsimikas, Rancho Santa Fe, CA (US); and Joseph L. Witztum, San Diego, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Appl. No. 17/290,843
Filed by The Regents of the University of California, Oakland, CA (US)
PCT Filed Nov. 1, 2019, PCT No. PCT/US2019/059433
§ 371(c)(1), (2) Date May 3, 2021,
PCT Pub. No. WO2020/092928, PCT Pub. Date May 7, 2020.
Claims priority of provisional application 62/755,366, filed on Nov. 2, 2018.
Prior Publication US 2021/0388116 A1, Dec. 16, 2021
Int. Cl. C07K 16/44 (2006.01); A61K 39/00 (2006.01); A61K 51/10 (2006.01); G01N 33/569 (2006.01); G01N 33/92 (2006.01)
CPC C07K 16/44 (2013.01) [A61K 51/1018 (2013.01); G01N 33/56966 (2013.01); G01N 33/92 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C12N 2510/02 (2013.01)] 16 Claims
 
1. An isolated antibody or antibody fragment comprising a variable heavy chain (VH) domain and a variable light chain (VL) domain;
wherein the VH domain comprises SEQ ID NO:2; and
wherein the VL domain comprises SEQ ID NO:4,
wherein the antibody or antibody fragment binds to an oxidized cholesteryl ester (OxCE) of arachidonic acid.